Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma

Seminars in Hematology

Volumn 48, Issue 1, 2011, Pages 4-12

  Zingone, Adriana ^a   Kuehl, W Michael ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; MICRORNA;

ARTICLE; BONE MARROW CELL; CAUCASIAN; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; HUMAN; MOLECULAR GENETICS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PLASMA CELL; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR CELL;

DISEASE PROGRESSION; HUMANS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA;

EID: 78650981573     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.11.003     Document Type: Article

References (65)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Kyle R.A., Kumar S. The significance of monoclonal gammopathy of undetermined significance. Haematologica 2009, 94:1641-1644.
3. Rajkumar S.V., Lacy M.Q., Kyle R.A. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007, 21:255-265.
4. Shapiro-Shelef M., Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005, 5:230-242.
5. Tarte K., Zhan F., De Vos J., Klein B., Shaughnessy J. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003, 102:592-600.
6. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2:175-187.
7. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362-1369.
8. Berenson J.R., Anderson K.C., Audell R.A., et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010, 150:28-38.
9. Dispenzieri A., Katzmann J.A., Kyle R.A., et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010, 375:1721-1728.
10. Muller A.M., Geibel A., Neumann H.P., et al. Primary (AL) amyloidosis in plasma cell disorders. Oncologist 2006, 11:824-830.
11. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003, 102:3759-3764.
12. Weiss B.M., Abadie J., Verma P., Howard RSKuehl W.M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113:5418-5422.
13. Landgren O., Gridley G., Turesson I., et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006, 107:904-906.
14. Landgren O., Kristinsson S.Y., Goldin L.R., et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 2009, 114:791-795.
15. Landgren O., Kyle R.A., Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
16. Dispenzieri A., Kyle R.A., Katzmann J.A., et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008, 111:785-789.
17. Rosinol L., Blade J., Esteve J., et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003, 123:631-636.
18. Kyle R.A., Durie B.G., Rajkumar S.V., et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127.
19. Waxman A.J., Kuehl M., Balakumaran A., Weiss BLandgren O. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk 2010, 10:248-257.
20. Ocqueteau M., Orfao A., Almeida J., et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998, 152:1655-1665.
21. Raja K.R., Kovarova LHajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010, 149:334-351.
22. Zhan F., Hardin J., Kordsmeier B., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757.
23. Zhan F., Tian E., Bumm K., Smith R., Barlogie B., Shaughnessy J. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003, 101:1128-1140.
24. Zhan F., Barlogie B., Arzoumanian V., et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007, 109:1692-1700.
25. Chng W.J., Glebov O., Bergsagel P.L., Kuehl W.M. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007, 20:571-596.
26. Pichiorri F., Suh S.S., Ladetto M., et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008, 105:12885-12890.
27. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12.
28. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
29. Stanganelli C., Arbelbide J., Fantl D.B., Corrado C., Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol 2010, 89:191-199.
30. Salhia B., Baker A., Ahmann G., Auclair D., Fonseca R., Carpten J. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. Cancer Res 2010, 70:6934-6944.
31. Yuregir O.O., Yurtcu E., Kizilkilic E., Kocer N.E., Ozdogu H., Sahin F.I. Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J Lab Hematol 2009, 32:142-149.
32. Takahashi T., Shivapurkar N., Reddy J., et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004, 10:2928-2935.
33. Mateos M.V., Garcia-Sanz R., Lopez-Perez R., et al. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2001, 2:146-149.
34. Dib A., Barlogie B., Shaughnessy J.D., Kuehl W.M. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007, 109:1337-1338.
35. Gonzalez-Paz N., Chng W.J., McClure R.F., et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109:1228-1232.
36. Rajkumar S.V., Kyle R.A., Therneau T.M., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005, 106:812-817.
37. Perez-Persona E., Vidriales M.B., Mateo G., et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007, 110:2586-2592.
38. Perez-Persona E., Mateo G., Garcia-Sanz R., et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010, 148:110-114.
39. Chiecchio L., Dagrada G.P., Ibrahim A.H., et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009, 94:1708-1713.
40. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
41. Chng W.J., Fonseca R. Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen 2009, 50:697-707.
42. Bergsagel P.L., Kuehl W.M., Zhan F., Sawyer J., Barlogie B., Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106:296-303.
43. Avet-Loiseau H., Facon T., Grosbois B., et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002, 99:2185-2191.
44. Bergsagel P.L., Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 2001, 20:5611-5622.
45. Gabrea A., Bergsagel L.P., Kuehl M.W. Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair (Amst) 2006, 5:1225-1233.
46. Avet-Loiseau H., Facon T., Daviet A., et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999, 59:4546-4550.
47. Avet-Loiseau H., Garand R., Lode L., Harousseau J.L., Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003, 101:1570-1571.
48. Bochtler T., Hegenbart U., Cremer F.W., et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008, 111:4700-4705.
49. Harrison C.J., Mazzullo H., Ross F.M., et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002, 117:427-435.
50. Hayman S.R., Bailey R.J., Jalal S.M., et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001, 98:2266-2268.
51. Gabrea A., Martelli M.L., Qi Y., et al. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer 2008, 47:573-590.
52. Avet-Loiseau H., Gerson F., Magrangeas F., Minvielle S., Harousseau J.L., Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001, 98:3082-3086.
53. Smadja N.V., Leroux D., Soulier J., et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003, 38:234-239.
54. Fonseca R., Debes-Marun C.S., Picken E.B., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003, 102:2562-2567.
55. Fonseca R., Oken M.M., Harrington D., et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001, 15:981-986.
56. Chng W.J., Van Wier S.A., Ahmann G.J., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005, 106:2156-2161.
57. Konigsberg R., Ackermann J., Kaufmann H., et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 2000, 14:1975-1979.
58. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
59. Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
60. Rasmussen T., Kuehl M., Lodahl M., Johnsen H.E., Dahl I.M. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005, 105:317-323.
61. Chng W.J., Gonzalez-Paz N., Price-Troska T., et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008, 22:2280-2284.
62. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001, 18:212-224.
63. Haigis K.M., Kendall K.R., Wang Y., et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008, 40:600-608.
64. Chesi M., Robbiani D.F., Sebag M., et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13:167-180.
65. Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008, 25-31.